UNSPSC 51271907: Butacaine sulfate

This classification denotes an anesthetic agent with the molecular formula 2C18H30N2O2.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PAU39W3CVB, chemically known as 1-propanol, 3-(dibutylamino)-, p-aminobenzoate (ester), sulfate (2:1) but generally known as butacaine sulfate, which bears US NIH Compound Identifier 120185. European Medicines Agency schedules Butacaine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00907MIG.

Most nations schedule butacaine sulfate under HS 29224995 and SITC 51465. As of Q4 2014, BUTACAINE SULFATE remains the US FDA Preferred Term for this commodity. Butacaine sulfate bears US NLM identifiers UMLS ID C0521936 and NCI Concept Code C77320. SMILES: CCCCN(CCCC)CCCOC(=O)C1=CC=C(C=C1)N.CCCCN(CCCC)CCCOC(=O)C1=CC=C(C=C1)N.OS(=O)(=O)O.

UNSPSC 51271907 Butacaine sulfate, a Commodity code, describes local anesthetic pharmaceutical products that state and local procurement offices acquire through cooperative purchasing arrangements and multi-source pharmaceutical contracts. Recent solicitation activity shows state and local buyers procuring generic and branded pharmaceuticals—including local anesthetics and topical agents—via established supply agreements with authorized pharmaceutical wholesalers, often bundled into broader pharmaceutical procurement frameworks rather than purchased as single-product line items. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents a typical issuing body for this code, coordinating multi-state procurement on behalf of participating state agencies, local governments, and health care facilities across member jurisdictions. These contracts typically require manufacturers and authorized vendors to maintain regulatory compliance with FDA requirements and cGMP standards, manage relationships with designated wholesalers, and submit detailed product specifications including National Drug Codes (NDCs), SKUs, and packaging configurations.

MMCAP's January 2026 RFP for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, exemplifies current activity under this code. The solicitation encompasses pharmaceuticals distributed across participating state and local government facilities in Minnesota, Oregon, and other member states, with products required to be available in the marketplace by May 15, 2026 and contracts effective July 1, 2026. Vendors must maintain contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health, and Morris & Dickson Co., LLC), comply with the Drug Supply Chain Security Act (DSCSA), carry professional liability and commercial general liability insurance, and accept a 3 percent administrative fee on all contract purchases. Evaluation emphasizes price competitiveness (75 percent of scoring), with secondary weight on fixed pricing, administrative compliance, EDI capability, and fee acceptance. The contract term is two years for new responders with optional extensions at MMCAP's discretion.